Last reviewed · How we verify

NCT05403736: CARMA

Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial

Completed NA Last updated 6 February 2025
What this trial tests

NA trial testing Cardiac Aggressive Risk MitigAtion Plan in Cancer in 20 participants. Completed in 16 June 2023.

Timeline
7 October 2022
Primary endpoint
16 June 2023
16 June 2023

Quick facts

Lead sponsorCedars-Sinai Medical Center
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment20
Start date7 October 2022
Primary completion16 June 2023
Estimated completion16 June 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Cedars-Sinai Medical Center

Who can join

18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to examine adherence to cardio-oncology consultation.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Cardiotoxicity following thoracic radiotherapy for lung cancer.
    Walls GM, Bergom C, Mitchell JD, Rentschler SL, et al · · 2025 · cited 21× · PMID 39506136 · DOI 10.1038/s41416-024-02888-0
  2. Early cardio-oncology intervention in thoracic radiotherapy: prospective single-arm pilot study.
    Zhang SC, Gasho JO, Eno C, Silos KD, et al · · 2025 · cited 2× · PMID 39962137 · DOI 10.1038/s43856-025-00761-6

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other Cedars-Sinai Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05403736.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing